Abstract
Gastric carcinogenesis is a multifactorial process described as a stepwise progression from non-active gastritis (NAG), chronic active gastritis (CAG), precursor lesions of gastric cancer (PLGC) and gastric adenocarcinoma. Gastric cancer (GC) 5-year survival rate is highly dependent upon stage of disease at diagnosis, which is based on endoscopy, biopsy and pathological examinations. Non-invasive GC biomarkers would facilitate its diagnosis at early stages leading to improved GC prognosis. We analyzed plasma samples collected from 80 patients diagnosed with NAG without H. pylori infection (NAG−), CAG with H. pylori infection (CAG+), PLGC and GC. A panel of 208 metabolites including acylcarnitines, amino acids and biogenic amines, sphingolipids, glycerophospholipids, hexoses, and tryptophan and phenylalanine metabolites were quantified using two complementary quantitative approaches: Biocrates AbsoluteIDQ®p180 kit and a LC-MS method designed for the analysis of 29 tryptophan pathway and phenylalanine metabolites. Significantly altered metabolic profiles were found in GC patients that allowing discrimination from NAG−, CAG+ and PLGC patients. Pathway analysis showed significantly altered tryptophan and nitrogen metabolic pathways (FDR P < 0.01). Three metabolites (histidine, tryprophan and phenylacetylglutamine) discriminated between non-GC and GC groups. These metabolic signatures open new possibilities to improve surveillance of PLGC patients using a minimally invasive blood analysis.
Highlights
® Biocrates AbsoluteIDQ p180 kit and a LC-MS method designed for the analysis of 29 tryptophan pathway and phenylalanine metabolites
We present results obtained from the analysis of plasma samples collected from 80 patients diagnosed with non-active gastritis (NAG)−, chronic active gastritis (CAG)+, precursor lesions of gastric cancer (PLGC) and Gastric cancer (GC) using a combination of mass spectrometry-based methods for the quantification of a total of 208 metabolites including acylcarnitines, amino acids and biogenic amines, sphingolipids, glycerophospholipids, hexoses, tryptophan and phenylalanine metabolites
The PC1 vs PC2 scores plot obtained from the Principal component analysis (PCA) model of the data set explaining 22% of the total variance showed a high overlap of NAG−, CAG+, PLGC or GC samples
Summary
® Biocrates AbsoluteIDQ p180 kit and a LC-MS method designed for the analysis of 29 tryptophan pathway and phenylalanine metabolites. Altered metabolic profiles were found in GC patients that allowing discrimination from NAG−, CAG+ and PLGC patients. Three metabolites (histidine, tryprophan and phenylacetylglutamine) discriminated between non-GC and GC groups These metabolic signatures open new possibilities to improve surveillance of PLGC patients using a minimally invasive blood analysis. Gas chromatography hyphenated to mass spectrometry and 1H-NMR has been used to profile urinary metabolites on urine samples to discriminate between GC patients and healthy volunteers[19,20]. Gas chromatography – high resolution time-of-flight mass spectrometric analysis of plasma samples from chronic active gastritis and GC patients showed different metabolic profiles associated to oxidative stress, and perturbed metabolism of amino acids and fatty acids[21]. Results obtained from the analysis of plasma samples from GC patients showed significant alterations in the plasma free amino acids profiles[22]. Results indicated that the observed metabolic changes could not be attributted to differences in the distribution of H. pylori infection across the groups of patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
